We enrolled 23 patients with relapsed follicular lymphoma (FL) in a prospective single-arm study of auto-SCT combined with in vivo rituximab graft purging and post transplant rituximab maintenance. Minimal residual disease was monitored with quantitative PCR testing. With a median follow-up of 74.2 months, neither median overall survival (OS) nor PFS has been reached. Here, 5-year OS and 5-year PFS are 78% (95% confidence interval (CI) 61-95%) and 59% (95% CI 38-80%), respectively. Time to progression (TTP) with the experimental regimen was significantly improved compared with TTP with the last prior treatment (Po0.001). Durable molecular remissions occurred in 11 of 13 assessable patients. PFS was significantly longer in patients who achieved a molecular remission by 3 months post-auto-SCT (P ¼ 0.001). Prolonged hypogammaglobulinemia occurred in most patients; however, no increase in major infections was observed.
Introduction
During the past decade, major advances have occurred in the management of patients with follicular lymphoma (FL). Recent multi-center data suggest that, since the introduction of combined chemo-immunotherapy, the natural history of FL may have changed for the better.
1 Dose intensification using high-dose chemotherapy (HDT) and auto-SCT has been reported to prolong remissions in patients with recurrent disease. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] A recent randomized comparison of auto-SCT versus salvage chemotherapy for relapsed FL showed high response rates, acceptable toxicities and improved PFS and overall survival (OS). 16 Unfortunately, cure has still not been shown with either antibody-based treatment or auto-SCT.
There are two putative sources of lymphoma cells after HDT/auto-SCT for FL: (1) residual malignant cells that survive HDT and (2) lymphoma cells that are re-introduced through infusion of a contaminated graft. After auto-SCT, FL relapses are frequently located at sites of previous disease, 17 suggesting that tumor cells remain despite highdose therapy. In addition, BM and PBSC harvests from patients with B-cell malignancies are recognized to frequently contain malignant cells. [18] [19] [20] [21] Studies employing genetic markers have implicated these graft contaminants as a potential source of relapse post-auto-SCT. 22, 23 Strategies to decrease FL relapse post-auto-SCT must reduce or eliminate both of these sources of lymphoma cells.
Rituximab has significant activity in FL as a single agent and in combination with chemotherapy. 24, 25 In addition, it has been employed to purge stem cell harvests in vivo [26] [27] [28] [29] and has produced prolonged clinical and molecular remissions when given after auto-SCT. 30 Quantitative PCR assays are capable of detecting as few as one malignant cell in 10 5 cells. 31 As a result, molecular remission status has been used as a surrogate marker of FL disease burden after treatment. 32 Patients who become PCR negative for BCL2/JH rearrangements in peripheral blood (PB) or BM after treatment are reported to have superior survival compared with those who remain positive. 9, [33] [34] [35] This observation suggests that achieving a minimal residual disease (MRD) state after auto-SCT may be an important clinical goal as it has been associated with improved OS.
We report a prospective phase II study of a novel treatment strategy for relapsed high-risk FL. Our strategy combined an in vivo rituximab purge with HDT and auto-SCT, followed by rituximab maintenance therapy. We monitored patients for molecular contamination of the graft and for MRD after auto-SCT. We also monitored patients' serum Ig levels pretreatment and for several years post transplant.
Materials and methods
Consecutive patients with stage III or IV relapsed FL, who were 18-65 years of age and had good performance status (Eastern Cooperative Oncology Group (ECOG) o2), were entered onto this dual center, single-arm phase II clinical trial between June 1998 and April 2000. The presence of one or more of the following high-risk features was required: preceding remission lasting o12 months, presence of B symptoms, high lactate dehydrogenase or nodal bulk 45 cm. Patients were excluded if they had involvement of the central nervous system, a history of other malignancy (excluding non-melanoma skin carcinoma or cervical carcinoma stage I), pregnancy or refusal to practice contraception if fertile, serious non-malignant cardiac, renal, hepatic or neurological disease, serious active infection, HIV seropositivity, allergy to study agents, presence of human anti-murine antibodies or earlier treatment with rituximab. Patients were treated at Toronto-Sunnybrook Regional Cancer Center or Princess Margaret Hospital. The trial had full approval from the hospitals' Institutional Review Boards, and informed consent was obtained from every patient before enrollment.
Study patients with no earlier exposure to anthracycline received salvage chemotherapy with CHOP. 36 Patients who had earlier received anthracycline were given DHAP. 37 Patients who achieved less than 75% reduction in measurable disease after 2-6 cycles of CHOP could be treated with DHAP (2-6 cycles), and those with less than 75% reduction to DHAP could be treated with mini-BEAM 38 at the discretion of the treating physician. Stem cell collection took place when less than 15% of BM was involved with lymphoma. PBSCs were mobilized with 5-10 days of G-CSF at 10 mg/kg/day. A single infusion of rituximab at 375 mg/m 2 was given intravenously as an in vivo purge. Seven patients received the rituximab infusion on the third day of G-CSF and the remaining patients were treated 3 days before initiation of G-CSF. Those patients who achieved greater than or equal to 75% reduction in measurable disease after salvage chemotherapy proceeded to HDT conditioning with CBV (cyclophosphamide, BCNU, etoposide) 39 followed by autologous stem cell infusion. Two 4-week courses of rituximab at 375 mg/m 2 were administered intravenously as maintenance therapy 8 and 24 weeks after auto-SCT.
Patient follow-up and molecular monitoring Response to therapy was assessed by serial clinical examination, routine blood work, quantification of serum Igs, BM aspirate and biopsy for morphologic and molecular assessment, and computed tomography scans at 3, 6, 9 and 12 months post-auto-SCT, and every 6 months thereafter. Morphologically positive baseline samples of lymph node, BM and PB were assessed by PCR for the presence of detectable BCL2/JH rearrangements or clonal VDJ rearrangements. Quantitative real-time PCR was used to allow for a sensitivity of one positive cell per 10 4 -10
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. Real-time PCR was performed with QuantiTect SYBR Green I (Qiagen, Mississauga, ON, Canada) on a DNA Engine Opticon I (Bio-Rad, Mississauga, ON, Canada). 31 Molecular monitoring for MRD was performed on all follow-up PB and BM samples in patients in whom a molecular marker could be detected at baseline. Similar analyses were performed on the stem cell graft to detect the presence of occult contamination. All samples were analyzed in triplicate.
End points and statistical considerations
The primary outcome was PFS. Assuming that 4-year PFS among patients with relapsed FL was approximately 50% after auto-SCT alone, 16 our sample size of 23 patients allowed us to detect a greater than or equal to 28% improvement in 4-year PFS with 80% power and 95% confidence. Secondary outcomes were OS, regimen-related toxicity (including infections) and MRD in the PB, BM and stem cell graft. Serum Ig levels and time to progression (TTP) were assessed post hoc. OS, PFS and TTP were measured from the date of enrollment in the study, defined according to standardized response criteria, 40 and determined by the method of Kaplan and Meier. 41 'TTP with the last prior chemotherapy' was defined as the time from initiation of last prior treatment to the time of progression. Time-to-event comparisons were analyzed with the log-rank test and expressed as Kaplan-Meier plots. Serum Ig levels preapheresis and post-treatment were compared with Fisher's exact test. All results were considered significant at the 5% level (Po0.05). The Cox proportional hazards assumption was confirmed for all time-to-event comparisons. All statistical analyses were completed with SAS version 9.1. Toxicity was graded using the NCIC Common Terminology Criteria for Adverse Events (CTCAE).
Results

Patients
Patient characteristics are summarized in Table 1 (two patients were omitted because of incomplete data). Before study enrollment, patients were treated with a median of one prior chemotherapy regimen. All patients had earlier received alkylator-based regimens, and 12 (52%) had received anthracycline. All patients were symptomatic at the time of study entry. One-third of the patients (7/21) had intermediate or high-risk follicular lymphoma international prognostic index scores (see Table 1 ). 42 
Treatment
In total, 8 patients received CHOP, 10 received DHAP, 3 received CHOP þ DHAP and 2 received DHAP þ mini-BEAM before auto-SCT. One patient was taken off the study because of a failure to collect sufficient numbers of stem cells and was subsequently lost to follow-up (patient not included in results). Twenty-three patients received high-dose therapy and SCT. In total, 21 of 23 patients received both planned cycles of maintenance rituximab with 177 of 184 planned doses infused. Only three patients had significant dose delays. The lengths of the delays were 82, 121 and 128 days in the first cycle. One of these patients developed a systemic infection and did not receive the second dose, whereas the other two patients did receive the second course of rituximab. Another patient had the second cycle of maintenance rituximab withheld because of an active infection.
Response to therapy
Progressive improvements in clinical response followed each phase of the protocol. Following salvage chemotherapy, 6 patients (26%) had a CR or unconfirmed CR (CRu) and 17 (74%) had a partial response. At 3 months after HDT/auto-SCT, the rate of CR/CRu had improved to 21/23 (91%). After completing rituximab maintenance, 21 patients were still in CR or unconfirmed CR (CRu).
Survival and progression
At a median follow-up of 74 months, 16 of 23 patients were alive. Median OS and PFS were not yet reached (Figure 1) . Here, 5-year OS and 5-year PFS were 78% (95% confidence interval (CI) 61-95%) and 59% (95% CI 38-80%), respectively. Furthermore, 12 of 16 survivors were free from progression of disease, with 10 of 12 in continued CR or CRu. Ten patients relapsed, at a median of 33.5 months post-enrollment (range 23-62). Seven patients died:
five from disease progression, one of sudden cardiac death at 15.5 months with no evidence of progression, and one from secondary acute leukemia at 67.8 months with concurrent FL progression. For the 21 patients with available data, TTP following the experimental protocol was significantly improved compared with TTP of the same patients with their last prior chemotherapy (Figure 2 ).
Toxicity
There were no serious adverse events with salvage chemotherapy or with HDT/auto-SCT, including no TRM. Median stem cell collection was 3.07 Â 10 6 /kg CD34 þ cells (range 2.25-6.90). The median days to neutrophil recovery was 10 (range 9-14). All patients required platelet and RBC transfusions after HDT/auto-SCT. A median of 3 U of platelets and 4 U of packed red cells were transfused. In total, 21 of 23 patients (91%) experienced febrile neutropenia after HDT, with a median duration of 9 days (range 2-12). Eight cases were associated with documented bacteremia. Hospital stays after HDT were 18-42 days (median 21 days).
Eleven episodes of early (p3 months post transplant) pneumonia occurred in five patients, including one grade 3 bacterial pneumonia and one grade 4 fungal pneumonia. In addition, 10 patients developed cough and/or dyspnea associated with interstitial infiltrates (7 cases), or pulmonary nodules (3 cases) at a median of 2.6 months post-auto-SCT (range 1-9.8 months). Bronchoscopy diagnosed one case of atypical mycobacterial infection; no other etiologies were found. Patients with interstitial pneumonitis and no evidence of infection were treated with prednisone (1 mg/ kg/day) for presumed carmustine toxicity; all patients improved. Three patients experienced grade 4 neutropenia during maintenance rituximab lasting for 7, 10 and 30 days, respectively. One patient had fluctuating grade 2 neutropenia lasting for 18 months. There were four episodes of herpes zoster reactivation, two in the acute period (one disseminated grade 3) and two more than 2 years post-auto-SCT. Other toxicities included one case of resolved grade 3 acute renal failure in the peritransplant period, one episode of grade 4 thrombotic microangiopathy at 6.8 months post-auto-SCT and 1 episode of grade 3 optic neuritis at 6.8 months post-auto-SCT. To date, there have been two cases of secondary malignancy: a fatal case of AML that developed 56 months post-auto-SCT and a case of primary carcinoma of the lung that occurred 43 months post-auto-SCT.
As illustrated in Figure 3 , significant and prolonged suppression of serum Igs was noted. Before auto-SCT, only 5 of 12 assessable patients had serum IgG below the lower limit of normal. After auto-SCT and maintenance rituximab, most assessable patients had serum IgG levels below the lower limit of normal for at least 4 years (Po0.05). Statistical significance was lost beyond this time point because of the low number of patients with measurements. In some patients, serum IgG levels had not recovered when last measured more than 8 years post-treatment. Similar trends were noted in serum IgA levels. In contrast, serum IgM levels appeared to recover more quickly after treatment (see Figure 3) . There was one patient with prolonged hypogammaglobulinemia who had repeated episodes of bacterial sinus infections requiring treatment with antibiotics. She was started on intravenous Ig treatments 5.5 years post transplant and experienced improvement with the sinusitis. There were no other serious cases of bacterial infection in the late follow-up period.
Molecular monitoring of residual disease
At enrollment, 13 of 23 patients (56.5%) had detectable BCL2/JH rearrangements (12 patients) or patient-specific VDJ rearrangements (1 patient) by PCR amplification in lymph node, BM or PB (Figure 4 ). We could not determine whether the quantitative PCR involvement of BM at the time of entry into the study predicted early relapse, as some patients with high involvement have remained in remission beyond 60 months post transplant. Of these 13 informative patients, only 2 (17%) received a PCR-negative graft despite treatment with rituximab before stem cell collection. These two patients (patient nos. 5 and 6 in Figure 4 who achieved a molecular remission by 3 months postauto-SCT experienced significantly longer PFS than those with MRD detected at the same time point (P ¼ 0.001; Figure 5 ). OS was not significantly different. Two patients (Figure 4 ; patient nos. 2 and 9) experienced clinical relapse without evidence of molecular relapse in BM or PB. However, a lymph node biopsy specimen taken at relapse of patient no. 2 was analyzed by PCR and confirmed the re-occurrence of the same lymphoma clone detected before apheresis. Patient no. 9 was diagnosed with secondary leukemia before death and was also found to have recurrent adenopathy on computed tomography that was thought to represent his lymphoma.
Discussion
The combination of HDT/auto-SCT with rituximab purging and maintenance was safe and generally well tolerated in this study. However, profound suppression of humoral immunity was noted in almost all patients. The prolonged hypogammaglobulinemia observed in this study contrasts with the expected Ig recovery of IgM at 4-6 months, IgG at 7-9 months and IgA up to 2 years post unpurged autologous BMT without maintenance rituximab. 43, 44 Our findings also differ from the pivotal trial of rituximab monotherapy on 166 heavily pretreated low-grade nonHodgkin's lymphoma (NHL) patients in which only 14% of patients experienced a significant decline in Ig levels. 25 The combination of HDT/auto-SCT with rituximab has earlier been implicated in a delayed recovery of humoral immunity and is likely because of marked B-cell depletion. [45] [46] [47] Shortt and Spencer 48 found that reduction in IgG, IgA and IgM occurred in a group of 11 patients who received four weekly infusions of rituximab at 2 months post-HDT/auto-SCT. These reduced levels persisted in most patients when assessed up to 2 years post transplant. More recently, Lim et al. 49 extended the analysis from their earlier report 45 on 15 patients who received eight infusions of post-auto-SCT maintenance rituximab every 3 months over 2 years. With a median follow-up of 28 months (range 6-64), none of the 15 patients showed normalization of IgG, but two patients showed normalized IgA and two showed normalized IgM. It took 36 months for 60% of patients to attain 75% of the lowest normal IgG and 48 months for half the patients to recover 75% of the lowest normal IgA levels. However, even after 64 months, only 35% of patients had attained 75% of the lowest normal IgM levels. In Lim's report, the severe suppression of Ig seemed to have clinical relevance as 6 of 15 patients developed recurrent upper respiratory tract infections.
Our data extend these results by suggesting that most patients continue to have Ig levels well below the lower limit of normal well beyond 36 months. However, we have observed recovery of IgM in many patients after 3.5 years. This may suggest early B-cell recovery on stimulation without concomitant class switching. This may also explain why we did not see recurrent bacterial infections in most patients.
The combination of rituximab purging and maintenance with HDT/auto-SCT may impair humoral immunity by depleting the pool of memory B cells that normally replenish circulating plasma cells. susceptibility to infections, although most studies of rituximab (including our own) have not reported an increased incidence of opportunistic infections, 30, 46, 47 with the exception of some reports of increased cytomegalovirus and herpes zoster. 51, 52 Hypogammaglobulinemia may be expected to be even more profound in contemporary patient cohorts who have received rituximab combination or maintenance as part of both their initial and relapse therapies.
Both graft contamination and resistance to high-dose therapy likely contribute to FL relapse after HDT/auto-SCT. 9, 53 To combat these two potential sources of relapse, we combined HDT/auto-SCT with in vivo rituximab graft purging and post transplant rituximab maintenance therapy. This strategy achieved excellent disease control in patients with relapsed high-risk FL. Here, 5-year PFS was 59%, which is comparable or superior to results reported by other centers. 3, 8, [14] [15] [16] However, as our trial is a relatively small phase II study, comparisons with other reports should be interpreted with caution.
To gain further insight into the relative efficacy of our regimen, we compared TTP with our experimental regimen to TTP with last prior therapy for the same group of patients. We found that TTP was significantly improved with the experimental regimen. This comparison is encouraging, but should be considered within the context of our trial's limitations. More than 50% of patients in our trial received anthracycline for the first time in the studythus, one would anticipate some improvement in the response rate and duration. Even more importantly, all patients were rituximab-naive before enrollment. The addition of rituximab to induction chemotherapy and/or as maintenance significantly improve PFS and OS in both previously untreated and relapsed FL. 24, [54] [55] [56] The relative contributions of HDT/auto-SCT, rituximab purging and rituximab maintenance to the observed outcome in the current study are unknown. It is also unclear whether the results we obtained can be extrapolated to patients with earlier exposure to rituximab. Emerging evidence suggests that rituximab remains active in the re-treatment setting; 57, 58 however, more data are required. Moreover, molecular monitoring with quantitative PCR for MRD was possible in 13 of 23 patients in our study. Despite residual graft contamination in almost all patients, 10 of 13 assessable patients became PCR negative after auto-SCT. These 10 patients experienced superior PFS compared with patients who still had molecular evidence of disease after auto-SCT. This finding supports the concept that there is a contamination threshold below which infused tumor cells may be too few to re-establish clinical disease. 26 Seven patients achieved molecular remission of greater than 4 years. At the time of writing, six of these seven patients were in continuous CR, whereas one relapsed 62 months after enrollment. Thus, our results add to the growing body of literature, which suggests that molecular remission is an important predictor of long-term prognosis in FL. 32, 33, 51, 59 We administered a single dose of rituximab to patients before stem cell collection as an in vivo purge. Belhadj et al. 28 and Arcaini et al. 29 used a similar strategy and achieved PCR-negative stem cell collections in 9 of 11, and 9 of 9 patients, respectively. In our hands, this strategy proved to be incomplete and only 2 of 13 assessable patients had uncontaminated grafts. Nonetheless, compared with results from another study at our center using the same stem cell collection procedure but without the in vivo rituximab purge, where we detected a median of 0.1% contamination, the addition of rituximab decreased contamination to 0.002%, a 50-fold reduction (a median of 0.1% contamination reduced to 0.002%). 31, 33 We observed a significant incidence of non-fatal pulmonary toxicity. Single agent rituximab has been associated with interstitial pneumonitis, 60 and the risk of pulmonary toxicity with carmustine is well described. 46 It is possible that in combination these drugs have greater pulmonary toxicity than when given alone; thus, it may be advisable to avoid carmustine when combining rituximab with HDT/auto-SCT. Delayed neutropenia was also noted in three patients and has been reported earlier with rituximab maintenance. 61 All cases resolved without complication.
Our study suggests that HDT/auto-SCT plus rituximab purging and maintenance can produce durable clinical and molecular remissions with acceptable toxicity. However, this approach appears to produce profound and prolonged hypogammaglobulinemia. Although recurrent serious infections were not a major problem in the current study, the long-term implications of hypogammaglobulinemia with regard to infectious risk and the potential need for revaccination remain to be determined. Moreover, it is possible that contemporary patients who typically receive multiple courses of rituximab during the course of their FL may experience even more pronounced hypogammaglobulinemia.
